Sitagliptin is an oral antihyperglycemic (anti-diabetic drug) of the dipeptidyl peptidase-4 (DPP-4) inhibitor class. It was developed and is marketed by Merck & Co. This enzyme-inhibiting drug is used either alone or in combination with other oral antihyperglycemic agents (such as metformin or a thiazolidinedione) for treatment of diabetes mellitus type 2. The benefit of this medicine is its lower side-effects (e.g., less hypoglycemia, less weight gain) in the control of blood glucose values. Exenatide (Byetta) also works by its effect on the incretin system.
DPP-4 Inhibitor Related Products:
Alogliptin benzoate; Linagliptin; Vildagliptin; Saxagliptin; Trelagliptin succinate; Omarigliptin; Teneligliptin hydrobromide; Saxagliptin hydrate; Trelagliptin; Saxagliptin HCL; Alogliptin